OVID
vs
S&P 500
OVID
S&P 500
Over the past 12 months, OVID has significantly outperformed S&P 500, delivering a return of +55% compared to the S&P 500's +14% growth.
Stocks Performance
OVID vs S&P 500
Performance Gap
OVID vs S&P 500
Performance By Year
OVID vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Ovid Therapeutics Inc
Glance View
Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company is headquartered in New York City, New York and currently employs 44 full-time employees. The company went IPO on 2017-05-05. The firm is focused on developing medicines for patients and families living with epilepsies, seizure-related disorders and neurological disorders. The Company’s programs include OV329 (GABA aminotransferase inhibitor), OV350, OV882, and OV815 and OV825. OV329 (GABA aminotransferase inhibitor) is a next-generation GABA aminotransferase inhibitor being developed for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms. OV329 functions by substantially reducing the activity of GABA aminotransferase (GABA-AT), a key enzyme responsible for the degradation of the brain’s major inhibitory neurotransmitter, GABA. OV350 is a small molecule that directly activates the KCC2 transporter, which is an important channel in seizure control. OV882, which is a short hairpin RNA (shRNA-551) for Angelman syndrome. OV815, which is a genetic therapy approach for KIF1A-associated neurological disorders.
